BioNTech gains rights to 4SC Discovery's potential cancer drugs

12/18/2012 | Genetic Engineering & Biotechnology News

4SC Discovery granted Germany-based BioNTech exclusive rights to market and commercialize its early-stage small molecule toll-like receptor agonists as immunotherapies for cancer. The research and licensing deal entitles 4SC to about $3.3 million upfront plus milestone and royalties. "Our goal is now to speed up and jointly develop a novel breakthrough therapy toward the market addressing the high medical need in the exciting field of cancer immunotherapy," 4SC Discovery Managing Director Daniel Vitt said.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT